Positives: it seems the testing product line is expanding, at least in terms of distributors, with another two deals likely to be signed this calendar year.
Negatives: it seems the phase 1 clinical trial has been pushed back by six months, to commencing in the June 23 quarter. Also they should have a handle on their September 22 quarter sales by now and the fact they stayed mum suggests nothing to write home about. They always have said that the sales build would be weighted to the back end of FY23 but it just seems there are no pleasant surprises on that front.
Ann: Investor Presentation October 2022, page-2
Add MAP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
-0.005(2.78%) |
Mkt cap ! $78.37M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.5¢ | $22.11K | 122.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12556 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 64647 | 3 |
View Market Depth
| Last trade - 15.50pm 02/10/2024 (20 minute delay) ? |
| MAP (ASX) Chart |